Spark Plug Pipe

via CannabisNewsWire – CannabisNewsAudio announces the Audio Press Release (APR) titled “Intangible Assets Power Growth, Acquisitions in the Pharmaceuticals Sector,” featuring Lexaria Bioscience Corp. (CNSX:LXX.CN) (OTC:LXRP).

To hear the CannabisNewsAudio version, visit:

To read the full editorial, visit:

Outside of China, Lexaria is one of the world’s biggest holders of cannabis patents with eight patents already granted. The company currently holds four patents in the United States and four in Australia, covering aspects of its work to make beneficial drugs more palatable and effective. In addition, the company has further patent applications in process in more than 40 countries as part of a concerted strategy to expand its patent portfolio. This is made possible by the focused, tangible research and development being carried out by the company and is ultimately driven by the need to develop and control intangible assets.

Lexaria has disclosed it expects four more patents to be granted in 2018, bringing its total to twelve. Of note, all twelve of these are within a single patent family — and Lexaria expects patent success across all nine families of its current applications. Indeed the company recently revealed that it has seven more patent families in the works. Lexaria’s goal is to have some 200 patents pending or granted which, if achieved, could turn the organization into an IP behemoth in the global cannabis industry.

About Lexaria Bioscience Corp.

Lexaria Bioscience Corp. licenses disruptive patented delivery technology that promotes healthier ingestion methods, lower overall dosing and higher effectiveness of lipophilic active molecules. Lexaria has multiple patents pending in over 40 countries around the world and has patents granted in the USA and in Australia for utilization of its DehydraTECH (Trademarked) delivery technology. Lexaria’s technology provides increases in intestinal absorption rates; more rapid delivery to the bloodstream; and important taste-masking benefits, for orally administered bioactive molecules including cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs), nicotine and other molecules. For more information, visit the company’s website at

About CannabisNewsWire (CNW)

CannabisNewsWire (“CNW”) is a specialized information service that (1) aggregates cannabis news, (2) provides CannabisNewsBreaks that quickly updates investors in the space, (3) enhances corporate press releases, (4) helps companies with distribution and optimization of social media, and (5) delivers comprehensive corporate communication solutions. CNW is uniquely positioned in the cannabis market with a strong team of journalists and writers who can help private and public companies reach a wide audience of investors, consumers, journalists and the general public through our ever-growing dissemination network of more than 5,000 key syndication outlets. CNW is bringing unparalleled visibility, recognition and content to the cannabis industry.

For more information please visit

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published:

Forward-Looking Statements

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company’s SEC filings. These risks and uncertainties could cause the company’s actual results to differ materially from those indicated in the forward-looking statements.

CNW Corporate Communications Contact:

CannabisNewsWire (CNW)

Denver, Colorado

303.498.7722 Office

<img src=”” alt=”” width=”1″ height=”1″/>

Stock Symbols